Ebola Outbreak Worsens: Why Control Remains Elusive & Global Response Steps Up

The Ebola outbreak in Congo and Uganda has now infected more than 1,200 people and killed at least 500 since January 2026, with cases rising faster than health authorities can contain them, according to the World Health Organization (WHO) and local health officials. Experts warn the epidemic remains "far from under control," driven by limited access to clean water, weak healthcare infrastructure, and delays in vaccination rollouts.

The WHO’s latest report, released June 18, 2026, states that the outbreak in the Democratic Republic of Congo (DRC) has spread to 12 districts, while Uganda’s first confirmed cases in two decades—linked to cross-border transmission—have now reached 37 infections. "The situation is critical," said Dr. Matshidiso Moeti, WHO Regional Director for Africa. "Without immediate scaling of response efforts, we risk seeing this become the deadliest Ebola outbreak in history."

The European Union has pledged €450 million ($485 million) to support vaccination campaigns, medical supplies, and training for frontline workers, while the G7 nations are pushing for stricter international travel protocols, including mandatory pre-departure testing for travelers from affected regions. Belgium’s Federal Agency for Medicines and Health Products (FAMHP) confirmed the risk to its population remains "extremely low," citing robust border controls and limited local transmission chains.

Why is the outbreak worsening despite vaccines and treatments?

Health officials cite three key factors: water shortages, logistical delays, and community resistance. Oxfam International reported that only 30% of affected villages in Congo have reliable access to clean water, forcing people to use contaminated sources—a primary driver of transmission. "Ebola spreads when people drink from the same river where infected bodies were washed," said Oxfam’s East Africa Director, Marieke van Woerden. "Without water, sanitation, and hygiene (WASH) interventions, the outbreak will keep growing."

Vaccination efforts have stalled due to supply chain bottlenecks. The WHO’s preferred vaccine, Ervebo (developed by Merck), is in short supply after global stockpiles were depleted during a 2024 outbreak in Guinea. Uganda has received only 10,000 doses so far, far below the 50,000 needed to immunize high-risk populations. "We’re playing catch-up," said Dr. Yonas Tegegn, Uganda’s Health Minister. "The vaccine is effective, but we need it faster."

How are Congo and Uganda responding differently?

The two countries’ approaches highlight the challenges of coordination. Congo, which has faced Ebola outbreaks since 1976, has deployed mobile vaccination teams and community health workers to remote areas. However, armed conflict in North Kivu province has disrupted response efforts, with WHO reporting that 15 health workers were attacked in May alone.

Uganda, meanwhile, is relying on mass testing and quarantine zones, but its healthcare system is overwhelmed. The country’s first Ebola treatment center, opened in Mbarara on June 10, has already reached capacity. "We’re treating patients in tents with limited supplies," said Dr. Rhoda Wanyenze, a Ugandan epidemiologist at Makerere University. "The infrastructure just wasn’t built for this scale."

What’s the risk to Europe—and how is the EU preparing?

The EU’s €450 million funding will go toward three priorities:

1. Accelerating vaccine production: Partnering with pharmaceutical firms to increase Ervebo output by 30% by September 2026.
2. Strengthening lab capacity: Upgrading diagnostic facilities in Congo and Uganda to reduce testing delays (currently averaging 7 days per sample).
3. Border surveillance: Expanding pre-departure screening at airports in Kenya and Rwanda, where most travelers from Congo transit.

Belgium’s FAMHP emphasized that the country’s low risk stems from its zero confirmed cases and strict airport protocols, including thermal scanning and contact tracing for all arrivals from high-risk zones. "We’re monitoring closely, but the immediate threat is contained," said FAMHP Director Dr. Anne Van Damme.

What happens next? Three critical questions

1. Will the G7’s travel restrictions work?
   The G7 proposal includes mandatory Ebola PCR testing for travelers from Congo and Uganda, but critics argue it may hinder aid workers’ mobility. The WHO has not yet endorsed the plan, citing concerns over false positives and disproportionate economic harm to affected nations.

   

2. Can vaccine production keep up?
   Merck aims to double Ervebo production by late 2026, but experts warn that supply chains remain fragile. A 2025 study in The Lancet found that 40% of vaccine doses in sub-Saharan Africa expire unused due to cold-chain failures.

3. How long until the outbreak peaks?
   Modeling from the Imperial College London suggests the outbreak could double in size by August if current trends continue. "The window to turn this around is closing," said Dr. Neil Ferguson, an infectious disease modeler. "We’ve seen this script before—delayed response leads to exponential growth."

The WHO’s emergency committee will reconvene on July 2, 2026, to assess whether the outbreak meets the criteria for a Public Health Emergency of International Concern (PHEIC)—a designation that could unlock faster global funding. As of now, the focus remains on local containment, but the race against time is far from over.